BAB VII

SIMPULAN DAN SARAN

7.1 Simpulan

a. Terdapat hubungan bermakna antara gradient warna strip test RDT antigen dengan *CT value* PCR virus SARS-CoV-2.

b. Terdapat hubungan searah antara gradien warna pada strip test RDT antigen berdasarkan ikatan antigen dan antibodi terhadap virus SARS-COV-2.

c. Terdapat hubungan berlawanan antara nilai *CT value* PCR terhadap virus SARS-COV-2.

7.2 Saran

Berdasarkan kesimpulan diatas maka peneliti memberikan saran-saran sebagai berikut:

7.2.1 Bagi Masyarakat

Pemeriksaan RDT antigen masih dapat digunakan bila didapat warna samar-samar sudah didapat positif COVID-19. Sedangkan bila didapat hasil negatif dengan gejala perlu ditindak lanjuti pemeriksaan PCR untuk menghindari *false negative* antigen. Hal ini juga berlaku untuk rumah sakit terutama yang akan melakukan perjalanan maupun mengikuti aktivitas lainnya, seperti seminar.

7.2.2 Bagi RS Sheila Medika dan RS National Hospital

Melihat perbedaan sensitivitas antara alat RDT antigen sesuai dengan kertas petunjuk dengan hasil sensitivitas baik RS Sheila Medika maupun RS National Hospital. Maka perlu adanya pengawasan terhadap mutu agar didapat *Quality Assurance* yang baik terhadap kualitas pengambilan dan pengolahan spesimen, transportasi spesimen, spesimen diambil saat infeksi masih sangat dini, dan teknis di laboratorium, karena mengacu hasil rata-rata false negatif 32,52 maka sensitivitas seharusnya didapat 97%.

7.2.3 Bagi Peneliti Selanjutnya

Dilakukan penelitian selanjutnya menganalisa hubungan RDT antigen dengan nilai acuan *CT value* PCR yang berbeda-beda, agar didapatkan sensitifitas diatas 80%.

DAFTAR PUSTAKA

1. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- A n update on the status. Vol. 7, Military Medical Research. 2020. DOI: 10.1186/s40779-020-00240-0

2. Wang Z, Qiang W, Ke H. A Handbook of 2019-nCoV Pneumonia Control and Prevention. Hubei Science and technology press. 2020;

3. World Health Organization I. Saran Penggunaan Tes Imunodiagnostik di Fasyankes (Point of Care) untuk COVID-19. 8 April. 2020;(Pernyataan Keilmuan).

4. Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. Journal of Clinical Virology. 2020;129. DOI: 10.1016/j.jcv.2020.104455

5. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). Vol. 30, Journal of Microbiology and Biotechnology. 2020. DOI: 10.4014/jmb.2003.03011

6. ECDC. An overview of the rapid test situation for COVID-19 diagnosis in the EU/EEA. European Centre for Disease Prevention and Control. 2020.

7. Hartantoro D, Nuryati A, Nuryani S. Uji diagnostik uji antigen sars-cov-2 pada pemeriksaan laboratorium covid-19. PUINOVAKESMAS. 2021;2(2). DOI: 10.29238/puinova.v2i2.1171

8. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020;25(3). DOI: 10.2807/1560-7917.ES.2020.25.3.2000045

9. D'souza R, Banerjee A. An Insight into Coronavirus: A Global Pandemic of the 21 st Century. International Journal of Science and Research. 2018; DOI: 10.21275/SR20402061244

10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223). DOI: 10.21275/SR20402061244

11. Kementerian Kesehatan Republik Indonesia. Pedoman Pencegahan dan Pengendalian Serta Definisi Coronavirus Disease (COVID-19). Germas. 2020;

12. Erlina Burhan, Fathiyah Isbaniah ADS. diagnosis & penatalaksanaan di indonesia. Vol. 67, perhimpunan dokter paru indonesia (PDPI). 2020.

13. RI KK. Pedoman Kesiapsiagaan Menghadapi Infeksi COVID-19. Kementrian Kesehatan Republik Indonesia. 2020;

14. Malaru CRE, Rondo AGEY, Wagiu CG. Gambaran Hasil CT-Scan Toraks pada Pasien Coronavirus Disease 2019 (COVID-19). e-CliniC. 2021;9(1). DOI: 10.21275/SR20402061244

15. WHO. SARS-CoV-2 genomic sequencing for public health goals. WHO - Interim guidance. 2021;(January).

16. Amalia H. Omicron penyebab COVID-19 sebagai variant of concern. Jurnal Biomedika dan Kesehatan. 2021;4(4). DOI: 10.18051/jbiomedkes.2021.v4.139-141

17. Yanti B, Hayatun U. Peran pemeriksaan radiologis pada diagnosis Coronavirus disease 2019. Jurnal Kedokteran Syiah Kuala. 2020;20(1). DOI: 10.24815/jks.v20i1.18300

18. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020. Pedoman Tatalaksana COVID-19. 2020.

19. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Who. 2020;2019(January).

20. WHO. Tes Diagnostik untuk SARS-CoV-2: Panduan interim. World Health Organization. 2020;(September).

21. Jungnick S, Hobmaier B, Mautner L, Hoyos M, Haase M, Baiker A, et al. Detection of the new SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in five SARS-CoV-2 rapid antigen tests (RATs), Germany, March 2021. Eurosurveillance. 2021;26(16). DOI: 10.24815/jks.v20i1.18300

22. Patriquin G, Davidson RJ, Hatchette TF, Head BM, Mejia E, Becker MG, et al. Generation of False-Positive SARS-CoV-2 Antigen Results with Testing Conditions outside Manufacturer Recommendations: A Scientific Approach to Pandemic Misinformation. Microbiology Spectrum. 2021;9(2). DOI: 10.24815/jks.v20i1.18300

23. Rabaan AA, Tirupathi R, Sule AA, Aldali J, Mutair A al, Alhumaid S, et al. Viral dynamics and real-time rt-pcr ct values correlation with disease severity in covid-19. Vol. 11, Diagnostics. 2021. DOI: 10.3390/diagnostics11061091

24. Bai H, Cai X, Zhag X. A comparison of PCR vs Immunoassay vs Crispr-Based Test (Landscape Coronavirus Disease 2019 test (COVID019 test) in vitro. OSF Preprint. 2020;37(20).

25. LeBlanc JJ, Gubbay JB, Li Y, Needle R, Arneson SR, Marcino D, et al. Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories. Journal of Clinical Virology. 2020;128. DOI: 10.1016/j.jcv.2020.104433

26. Lippi G, Adeli K, Adeli K, Ferrari M, Horvath AR, Koch D, et al. Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations. Vol. 58, Clinical Chemistry and Laboratory Medicine. 2020. DOI: 10.1515/cclm-2020-0633